Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostatin + etoposide + carboplatin
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral (only For Etoposide, In Some Regimens)
01
Overview
**endostatin + etoposide + carboplatin** is a combination regimen used in the treatment of cancers, notably small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). **Endostatin** is an endogenous inhibitor of angiogenesis, working primarily by interfering with vascular endothelial growth factor (VEGF)-mediated pathways, thereby inhibiting tumor blood vessel formation and normalizing tumor vasculature. **Etoposide** is a topoisomerase II inhibitor that interferes with DNA synthesis, thus causing cell death in rapidly dividing tumor cells. **Carboplatin** is a platinum-based chemotherapeutic agent that alkylates and cross-links DNA, also inhibiting tumor cell replication. This regimen has been studied both in combination and sequentially, often with the aim to leverage endostatin’s anti-angiogenic activity to improve chemotherapeutic delivery and efficacy. Clinical studies (notably in China) suggest that adding endostatin to etoposide and carboplatin is tolerable, does not significantly worsen toxicity, and may offer improvement in quality of life and progression-free survival, although evidence for improvement in overall survival is limited[2][4].
- Brand names
- Endostar
- Other names
- endostatin plus etoposide and carboplatinrh-endostatin + etoposide + carboplatin
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on endostatin + etoposide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostatin + etoposide + carboplatin.